Pelago Bioscience Takes Strides Towards in vitro Diagnostic Application of CETSA®
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Pelago Bioscience has been awarded a 3.6M SEK Swelife grant to use its patented CETSA® technique to identify new oncology biomarkers to aid the treatment of childhood leukaemia.
Current treatment regimens are based on medication developed for adult cancers and there is little information to guide the appropriate regime in children, resulting in issues with reduced clinical efficacy and toxicity.
Pelago’s CETSA MS format can be used to profile the effect of a drug on up to 6000 proteins. This will be applied to patient blood samples and will identify ‘unique fingerprints’ associated with best clinical outcomes for each of 6 commonly used cancer drugs. Initially this profiling will be offered as a service but further studies will identify the key components of the finger print and reduce the number of proteins that need to be assessed. This will enable the development of a routine diagnostic assay.
CEO of Pelago Bioscience, Dr. Michael Dabrowski comments:
“Worldwide there are around 352,000 people diagnosed with a type of leukaemia each year, and it is the most common cancer in children and teens. Working in this area, and using our CETSA® technique to help identify new oncology biomarkers to support the treatment of children with leukaemia, has been hugely helped by the injection of grant funding from Swelife.”
Current treatment regimens are based on medication developed for adult cancers and there is little information to guide the appropriate regime in children, resulting in issues with reduced clinical efficacy and toxicity.
Pelago’s CETSA MS format can be used to profile the effect of a drug on up to 6000 proteins. This will be applied to patient blood samples and will identify ‘unique fingerprints’ associated with best clinical outcomes for each of 6 commonly used cancer drugs. Initially this profiling will be offered as a service but further studies will identify the key components of the finger print and reduce the number of proteins that need to be assessed. This will enable the development of a routine diagnostic assay.
CEO of Pelago Bioscience, Dr. Michael Dabrowski comments:
“Worldwide there are around 352,000 people diagnosed with a type of leukaemia each year, and it is the most common cancer in children and teens. Working in this area, and using our CETSA® technique to help identify new oncology biomarkers to support the treatment of children with leukaemia, has been hugely helped by the injection of grant funding from Swelife.”
